Bio-Rad Laboratories Inc
$ 320.06
-0.09%
04 Dec - close price
- Market Cap 8,633,566,000 USD
- Current Price $ 320.06
- High / Low $ 321.00 / 311.81
- Stock P/E N/A
- Book Value 249.75
- EPS -24.03
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.10 %
- 52 Week High 373.69
- 52 Week Low 211.43
About
Bio-Rad Laboratories, Inc. is a premier global provider of innovative solutions in life sciences research and clinical diagnostics, delivering a comprehensive portfolio of products and technologies designed to advance scientific discovery and enhance patient care. The company specializes in tools for genomic research, proteomics, and diagnostic testing, catering to the diverse needs of researchers and healthcare professionals. With a steadfast commitment to quality and reliability, Bio-Rad's extensive offerings, which include instruments, reagents, and advanced software, solidify its position as a leader in the biotechnology and healthcare industries.
Analyst Target Price
$348.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-30 | 2024-08-01 | 2024-05-07 | 2024-02-15 | 2023-10-26 | 2023-08-03 | 2023-05-04 | 2023-02-16 |
| Reported EPS | 2.26 | 2.61 | 2.54 | 2.9 | 2.01 | 3.11 | 2.29 | 3.1 | 2.33 | 3 | 3.34 | 3.31 |
| Estimated EPS | 1.94 | 1.75 | 1.78 | 2.88 | 1.18 | 2.01 | 2.15 | 2.82 | 2.78 | 2.68 | 3.54 | 3.45 |
| Surprise | 0.32 | 0.86 | 0.76 | 0.02 | 0.83 | 1.1 | 0.14 | 0.28 | -0.45 | 0.32 | -0.2 | -0.14 |
| Surprise Percentage | 16.4948% | 49.1429% | 42.6966% | 0.6944% | 70.339% | 54.7264% | 6.5116% | 9.9291% | -16.1871% | 11.9403% | -5.6497% | -4.058% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BIO
2025-10-25 01:45:00
Bio-Rad Laboratories and Biodesix are expanding their partnership to develop new in vitro diagnostic assays for oncology, leveraging Bio-Rad's Droplet Digital PCR technology. While the stock has seen a recent surge, its five-year returns remain negative, prompting questions about its current valuation. Analysts present differing fair value assessments, with some suggesting overvaluation while a Discounted Cash Flow model indicates significant undervaluation.
2025-10-14 22:26:20
This article from Investing.com India is an earnings call transcript for Bio-Rad Labs' Q2 2025, which indicates steady growth for the company. However, the full article content is replaced by an application error message, preventing the display of the actual transcript details.
2025-10-14 22:24:26
This article states that a client-side exception has occurred while loading the Investing.com Canada website, preventing the display of the Bio-Rad Labs Q2 2025 earnings call transcript. As a result, no information regarding the earnings call or Bio-Rad Labs' performance is available within the provided content. The current content is an error message.
2025-10-12 09:21:22
Sivik Global Healthcare LLC has made a new investment in Bio-Rad Laboratories, acquiring 18,000 shares valued at approximately $4.34 million, making it their 25th largest portfolio position. Bio-Rad Laboratories reported strong Q2 earnings with $2.61 EPS, surpassing analyst expectations, and revenue increased by 2.1% year-over-year. Institutional investors and hedge funds own 65.24% of the stock, indicating significant institutional interest in the medical research company.
2025-10-12 04:44:37
Bio-Rad Laboratories (NYSE:BIO.B) stock surged 15.3% to $284.88 during Friday's mid-day trading with a significant increase in trading volume. The company reported $2.61 EPS for the last quarter and revenue of $651.60 million, operating in life science research and clinical diagnostics. This report highlights company performance and financial metrics.
2025-07-31 20:22:00
Bio-Rad Laboratories reported strong Q2 2025 results, with EPS of $2.61 significantly surpassing the forecast of $1.73 and revenue reaching $651.6 million, exceeding expectations. Despite these positive financial outcomes, the company's stock experienced a 3.25% dip in aftermarket trading, reflecting broader market trends and ongoing challenges in the Chinese market and academic research funding. Bio-Rad also raised its full-year currency-neutral revenue guidance to flat to 1% growth and updated its operating margin projection to 12-13%, partly due to reduced tariff headwinds.
